Literature DB >> 13678138

Smallpox vaccine: contraindications, administration, and adverse reactions.

Douglas M Maurer1, Brian Harrington, J Michael Lane.   

Abstract

Since the terrorist attacks of September 11, 2001, and the anthrax exposures in the following weeks, concern that smallpox could be used as a biologic weapon has increased. Public health departments and the U.S. military have begun the process of vaccinating soldiers and civilian first-responders. Smallpox vaccination carries some serious risks: approximately one in 1 million primary vaccinees and one in 4 million revaccinees will die from adverse vaccine reactions. The most serious side effects of smallpox vaccine include progressive vaccinia, postvaccinial central nervous system disease, and eczema vaccinatum. Some of these reactions can be treated with vaccinia immune globulin or cidofovir. Proper patient screening and site care are essential. Family physicians must learn to screen potential vaccinees for contraindications (e.g., immunodeficiency, immunosuppression, certain skin and eye diseases, pregnancy, lactation, allergy to the vaccine or its components, moderate or severe intercurrent illness) and to treat vaccine-associated adverse reactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13678138

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  6 in total

1.  Failure of the smallpox vaccine to develop a skin lesion in vaccinia virus-naïve individuals is related to differences in antibody profiles before vaccination, not after.

Authors:  Xiaolin Tan; Sookhee Chun; Jozelyn Pablo; Philip Felgner; Xiaowu Liang; D Huw Davies
Journal:  Clin Vaccine Immunol       Date:  2012-01-18

Review 2.  Progress, prospects, and problems in Epstein-Barr virus vaccine development.

Authors:  Henry H Balfour
Journal:  Curr Opin Virol       Date:  2014-03-15       Impact factor: 7.090

3.  Poor Antigen Processing of Poxvirus Particles Limits CD4+ T Cell Recognition and Impacts Immunogenicity of the Inactivated Vaccine.

Authors:  Katherine S Forsyth; Brian DeHaven; Mark Mendonca; Sinu Paul; Alessandro Sette; Laurence C Eisenlohr
Journal:  J Immunol       Date:  2019-01-30       Impact factor: 5.422

4.  Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine.

Authors:  Huy Quang Quach; Inna G Ovsyannikova; Gregory A Poland; Richard B Kennedy
Journal:  Sci Rep       Date:  2022-09-13       Impact factor: 4.996

Review 5.  Extracting key information from historical data to quantify the transmission dynamics of smallpox.

Authors:  Hiroshi Nishiura; Stefan O Brockmann; Martin Eichner
Journal:  Theor Biol Med Model       Date:  2008-08-20       Impact factor: 2.432

6.  EPIPOX: Immunoinformatic Characterization of the Shared T-Cell Epitome between Variola Virus and Related Pathogenic Orthopoxviruses.

Authors:  Magdalena Molero-Abraham; John-Paul Glutting; Darren R Flower; Esther M Lafuente; Pedro A Reche
Journal:  J Immunol Res       Date:  2015-10-28       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.